

EXPRESS MAIL CERTIFICATE

4/14/03 EV294039683-US
Date Label No.

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.:



Docket No: 0630/1E791-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Vedrana S. SUSULIC; Emir DUZIC

Serial No.: 09/761,116

Art Unit: 1636

Confirmation No.: 3094

Filed: January 16, 2001

Examiner: Leffers Jr., Gerald

For: TRANSCRIPTIONAL REGULATION OF THE HUMAN BETA3 - ADRENERGIC RECEPTOR GENE

COURTESY COPY OF CLAIMS PENDING UPON
ENTRY OF ACCOMPANYING AMENDMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

April 14, 2003

Sir:

28. (Twice Amended) A method of screening for a compound that increases activity of an Sp1 or B segment-binding β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the Sp1 or B segment-binding β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting an increase in a level of activity of the Sp1 or B segment-binding β_3 -AR *trans*-activating factor, wherein the increase in the level of activity of the ^{human} Sp1 or B segment-binding β_3 -AR *trans*-activating factor results in an increase in the level of β_3 -AR gene product relative to a level of expression prior to contact with the test compound.

29. (Allowed) A method of screening for a compound that increases activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells ^{active} capable of producing the β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting an increase in a level of activity of the β_3 -AR *trans*-activating factor, wherein the increase in the level of activity of

the β_3 -AR *trans*-activating factor is detected by detecting an increase in the level of expression of a reporter gene operatively associated with an isolated nucleic acid having a nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) relative to a level of expression prior to contact with the test compound.

30. (Amended) A method according to claim 28, wherein the increase in the level of activity of the β_3 -AR *trans*-activating factor is detected by detecting an increase in the amount of β_3 -AR *trans*-activating factor present in the cells after contacting them with the test compound relative to the amount present prior to contact with the test compound.

31. A method according to claim 28, wherein the cells do not endogenously express, or express at very low level, β_3 -AR.

32. A method according to claim 31, wherein the cells are selected from the group consisting of HeLa cells, CV-1 cells, and WAT cells.

33. (Twice Amended) A method of screening for a compound that inhibits activity of an Sp1 or B segment-binding β_3 -adrenergic receptor (β_3 -AR)

trans-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the Sp1 or B segment-binding β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting a decrease in a level of activity of the Sp1 or B segment-binding β_3 -AR *trans*-activating factor,

wherein the decrease in the level of activity of the Sp1 or B segment-binding β_3 -AR *trans*-activating factor results in a decrease in the level of β_3 -AR gene product relative to a level of expression prior to contact with the test compound.

34. (Allowed) A method of screening for a compound that inhibits activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting a decrease in a level of activity of the β_3 -AR *trans*-activating factor,

wherein the decrease in the level of activity of the β_3 -AR *trans*-activating factor is detected by detecting a decrease in the level of expression of a reporter gene operatively associated with an isolated nucleic acid having a nucleotide sequence

GCCTCTGGGGAG (SEQ ID NO:1) relative to a level of expression prior to contact with the test compound.

35. A method according to claim 33, wherein the decrease in the level of activity of the β_3 -AR trans-activating factor is detected by detecting a decrease in the amount of β_3 -AR trans-activating factor present in the cells after contacting them with the test compound relative to the amount present prior to contact with the test compound.

36. A method according to claim 33, wherein the cells endogenously express β_3 -AR.

37. A method according to claim 36, wherein the cells are selected from the group consisting of neuroblastoma and BAT cells.

38. (Amended) A method of screening for a compound that increases activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in human cells, which method comprises:

(a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and

(b) detecting an increase in a level of activity of the β_3 -AR

trans-activating factor,

wherein the level of activity of the β_3 -AR *trans*-activating factor is detected by an increase in the level of expression of a reporter gene operatively associated with an isolated nucleic acid selected from the group consisting of:

(i) about a 7 kb genomic DNA 5' flanking region of a β_3 -AR

transcription start site,

(ii) a deletion construct of a 7 kb genomic DNA located upstream of a

β_3 -AR transcription start site;

(iii) a nucleic acid comprising a nucleotide sequence that is greater

than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1)

located 5' to an Sp-1 binding site relative to a transcription start site; and

(iv) a nucleic acid comprising a heterologous coding sequence

operatively associated with a promoter and operatively associated with a

nucleotide sequence that is greater than 80% identical to the nucleotide sequence

GCCTCTGGGGAG (SEQ ID NO:1) in proximity to an Sp-1 binding site, whereby

expression of the heterologous protein is regulated in a tissue specific manner.

39. (Amended) A method of screening for a compound that decreases activity of a β_3 -adrenergic receptor (β_3 -AR) *trans*-activating factor in

human cells, which method comprises:

- (a) contacting cells capable of producing the β_3 -AR *trans*-activating factor with a test compound; and
- (b) detecting a decrease in a level of activity of the β_3 -AR *trans*-activating factor, wherein the level of activity of the β_3 -AR *trans*-activating factor is detected by a decrease in the level of expression of a reporter gene operatively associated with an isolated nucleic acid selected from the group consisting of:

- (i) about a 7 kb genomic DNA 5' flanking region of a β_3 -AR transcription start site,
- (ii) a deletion construct of a 7 kb genomic DNA located upstream of a β_3 -AR transcription start site;
- (iii) a nucleic acid comprising a nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) located 5' to an Sp-1 binding site relative to a transcription start site; and
- (iv) a nucleic acid comprising a heterologous coding sequence operatively associated with a promoter and operatively associated with a nucleotide sequence that is greater than 80% identical to the nucleotide sequence GCCTCTGGGGAG (SEQ ID NO:1) in proximity to an Sp-1 binding site, whereby expression of the heterologous protein is regulated in a tissue specific manner.

M:\0630\1e791us1\HME0627.WPD